Siemens

The firm said the assay provides flexible automation and accurately identifies all six HCV genotypes as well as subtypes 1a and 1b.

Mergers and acquisitions in the omics space rose for the second year in a row, but the increase was significantly less than the 33 percent uptick in 2015 deals.

The firm sees the new panel as an important step forward in its strategy to further penetrate the molecular diagnostics market with its qPCR products.

The test can detect the presence of the Zika virus, which is an earlier warning of infection than indicated by anti-Zika antibodies. 

The deal gives Siemens Healthineers access to Neo New Oncology's next-generation sequencing-based assays and technology for tissue and biofluid specimens.

The companies will work together to pursue US Food and Drug Administration clearance for a workflow combining Siemens' sample prep module and Thermo's qPCR instrument.

The scientific products giants are exhibiting their combined workflow next week at the European Congress of Clinical Microbiology and Infectious Disease.

The firm also plans to launch its Versant MDx System sample prep module in the US next month for use with the test.

Agilent will pay Enzo $9 million to settle the suit, which involved a US patent issued to Enzo and describing non-porous solid supports for nucleic acids.

As part of a settlement deal, Siemens will pay Enzo an upfront fee of $9.5 million and potentially up to $5 million in licensing royalties.

Pages

Vivek Murthy is no longer the surgeon general of the US, the Associated Press reports.

People around the globe took to the streets to support science — some with signs.

Parents who learn of their increased genetic risk of disease also contend with telling their children about theirs, the New York Times writes.

In PLOS this week: loci linked to body mass index measurements, long non-coding RNA expression and urothelial carcinoma prognosis, and more.